Bayer shares jump after judge’s ruling on Roundup cancer claims

Bayer shares rose by more than 6 percent Friday, a day after a key court ruling in the upcoming trials over whether its Monsanto weedkillers can cause cancer. A federal judge overseeing the lawsuits late Thursday issued the order, which could severely restrict evidence that the plaintiffs consider crucial to their cases. Bayer shares were…
Business | New York Post

SPECIAL DISCOUNT UPDATE:

Bayer Sets Growth Targets Through 2022; Aims To Grow Sales By 4-5% Annually

The Bayer Group (BAYZF.PK, BAYRY.PK, BYR.L) announced the company aims to significantly enhance its performance in the coming years and has set itself ambitious growth and margin targets through 2022. The company is targeting sales growth of approximately 4 percent next year and an annual average of 4 to 5 percent in the following years through 2022, based on constant foreign exchange rates. This corresponds to an increase in sales from an anticipated 44.6 billion euros (pro forma) in 2018 to around 46 billion euros in 2019 and to approximately 52 billion euros in 2022.
RTT – Earnings

BEST DEAL UPDATE:

Roche takes on Loxo, Bayer in gene-defined cancer class

Roche’s entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.


Reuters: Science News

BEST DEAL UPDATE:

Spire.io – Over 50 Million Minutes of Calm Discovered!